Moleculin Biotech (MBRX) AI Stock Analysis

• Market Cap: $24.35M
• Dividend Yield: N/A
• Average Volume (3M): 4.06M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.77
• Revenue Growth: N/A
• EPS Growth: 60.64%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 49,498,577
• 10 Day Avg. Volume: 2,708,054
• 30 Day Avg. Volume: 4,058,839
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.10
• Enterprise Value/Revenue: -19.44
• Enterprise Value/Gross Profit: 87.48
• Enterprise Value/Ebitda: 0.09
• 1Y Price Target: $6.67
• Price Target Upside: 1261.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 44 Neutral
• Price Target: ―

Moleculin Biotech's stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

Positive Factors

Promising Clinical Trial Data

The promising Phase 2 results for Annamycin indicate strong potential for effective cancer treatment, enhancing Moleculin's competitive edge in oncology.

Regulatory Approvals

Securing regulatory approvals for the MIRACLE Phase 3 trial in Europe strengthens Moleculin's market position and accelerates its path to potential commercialization.

Financial Runway

A solid financial runway into late 2025 provides Moleculin with the necessary resources to advance its clinical trials and achieve key milestones.

Negative Factors

High Cash Burn Rate

The anticipated increase in cash burn rate poses a risk to Moleculin's financial stability, necessitating successful funding or revenue generation to sustain operations.

Delayed US Enrollment

Delays in US patient enrollment for the MIRACLE trial could hinder timely data collection and impact Moleculin's ability to meet critical development timelines.

Financial Instability

Moleculin's lack of revenue and growing losses highlight its financial instability, which could limit its ability to sustain long-term operations without successful product development.

Moleculin Biotech Business Overview & Revenue Model

Company Description

Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates. The company operates primarily in the biotechnology sector, specializing in the research and development of novel anti-cancer agents. Moleculin's core products include a portfolio of small-molecule drug candidates targeting highly resistant tumors and hard-to-treat cancers. The company's lead compounds are designed to disrupt cancer cell metabolism and enhance the body's immune response against tumors.

How the Company Makes Money

Moleculin Biotech primarily makes money through the development and potential commercialization of its oncology drug candidates. The company seeks to generate revenue by advancing its drug candidates through clinical trials and securing regulatory approvals. Revenue streams may include licensing agreements, collaborations with larger pharmaceutical companies, and potential sales of approved drugs. Additionally, Moleculin may receive milestone payments and royalties from partners involved in the commercialization of its drug candidates. The company's financial success heavily relies on its ability to successfully demonstrate the efficacy and safety of its drug candidates in clinical trials and to navigate the regulatory landscape for drug approvals.

Moleculin Biotech Financial Statement Overview

Summary

Moleculin Biotech is in a high-risk financial position typical for early-stage biotech firms. The absence of revenue and increasing losses emphasize the risky nature of its operations. Despite low leverage, the declining equity and assets raise concerns about sustainability. Continuous reliance on external funding underscores the need for successful product development to generate future revenues.

Income Statement

Moleculin Biotech has consistently reported zero revenue over the years, reflecting its pre-commercial stage typical in the biotech industry. The net income has been negative, with increasing losses each year, indicating growing expenses without revenue generation. This suggests a high-risk profile in terms of profitability and revenue generation.

Balance Sheet

The company's debt-to-equity ratio remains low due to minimal debt levels, which is positive for financial stability. However, the equity has been declining over the years, reflecting continuous operational losses. The equity ratio suggests a relatively moderate reliance on equity financing, but the declining trend in total assets highlights potential liquidity concerns.

Cash Flow

Moleculin Biotech has been consistently generating negative free cash flow, with no signs of improvement, reflecting its high cash burn rate common in biotech firms. The operating cash flow to net income ratio is high due to substantial operating losses. Financing cash flows have been positive, indicating reliance on external funding for operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	126.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-28.00K	-126.00K	-127.00K	-222.00K	-260.00K	-285.00K
EBITDA	-27.24M	-21.64M	-29.50M	-30.51M	-22.80M	-19.54M
Net Income	-26.55M	-21.76M	-29.77M	-29.02M	-15.89M	-17.36M
Balance Sheet
Total Assets	21.59M	16.93M	38.22M	57.42M	84.09M	29.03M
Cash, Cash Equivalents and Short-Term Investments	7.56M	4.28M	23.55M	43.15M	70.90M	15.17M
Total Debt	292.00K	478.00K	574.00K	451.00K	159.00K	277.00K
Total Liabilities	28.76M	10.95M	12.14M	5.23M	5.10M	11.27M
Stockholders Equity	-7.17M	5.98M	26.07M	52.19M	78.99M	17.76M
Cash Flow
Free Cash Flow	-21.34M	-23.88M	-24.23M	-27.71M	-18.97M	-18.15M
Operating Cash Flow	-21.34M	-23.86M	-24.10M	-27.64M	-18.95M	-17.77M
Investing Cash Flow	0.00	-13.00K	-124.00K	-67.00K	-19.00K	-374.00K
Financing Cash Flow	18.08M	4.63M	4.65M	-23.00K	74.72M	22.55M

Moleculin Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBRX, the sentiment is Negative. The current price of 0.49 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.54, and below the 200-day MA of 0.99, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 56.21 is Neutral, neither overbought nor oversold. The STOCH value of 84.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBRX.

Moleculin Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYBX	45 Neutral	$20.36M	-19.77	―	―	-100.00%	98.69%
MBRX	44 Neutral	$24.35M	―	-503.80%	―	―	60.64%
MRKR	44 Neutral	$12.29M	-0.69	―	―	44.55%	-17.92%
PHIO	42 Neutral	$12.77M	-0.67	―	―	―	85.26%
IMNN	41 Neutral	$13.06M	-0.38	―	―	―	45.96%
INAB	34 Underperform	$10.40M	-0.22	―	―	―	58.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Moleculin Biotech Corporate Events

Moleculin Biotech Unveils Promising Annamycin Data at AACR

On April 28, 2025, Moleculin Biotech presented new pre-clinical data for their drug Annamycin at the AACR Annual Meeting, highlighting its potential to expand into markets such as pancreatic cancer. The research suggests Annamycin can work synergistically with various FDA-approved anticancer drugs, potentially enhancing its clinical applications and attractiveness to future partners, which could significantly impact the company’s market positioning and stakeholder interest.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Underperform.

Moleculin Biotech’s stock score reflects the company’s high-risk financial position, characterized by no revenue and growing losses typical of early-stage biotech firms. The technical analysis signals bearish momentum, while the valuation highlights financial instability. Positive clinical trial developments and a solid cash position provide potential upside, but significant risks remain, especially regarding high trial costs and future funding needs.

To see Spark’s full report on MBRX stock, click here.

Moleculin Biotech Releases Corporate Presentation Online

On April 21, 2025, Moleculin Biotech, Inc. made a corporate presentation available on its website. The presentation is part of a Current Report on Form 8-K but is not filed under the Securities Exchange Act of 1934 or the Securities Act of 1933.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Underperform.

Moleculin Biotech faces significant financial challenges with no revenue and high cash burn, typical of early-stage biotech firms. Bearish technical indicators and negative valuation metrics reflect low investor confidence. However, positive developments in clinical trials and a solid financial runway offer potential upside if milestones are met. The overall risk remains high due to financial instability and the high costs associated with ongoing trials.

To see Spark’s full report on MBRX stock, click here.

Moleculin Biotech’s Annamycin Highlighted at AACR 2025

On April 17, 2025, Moleculin Biotech announced that their abstract on Annamycin, a next-generation anthracycline, was selected for a poster presentation at the AACR Annual Meeting 2025. This recognition highlights the potential of Annamycin in cancer treatment and strengthens Moleculin’s position in the pharmaceutical industry, particularly in developing innovative cancer therapies.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Underperform.

Moleculin Biotech faces significant financial challenges typical of early-stage biotech firms, with no revenue and increasing losses. The stock is under bearish technical indicators, reflecting low investor confidence. However, positive developments in clinical trials and a solid financial runway offer potential upside if milestones are met. The overall risk remains high due to financial instability and the high costs associated with ongoing trials.

To see Spark’s full report on MBRX stock, click here.

Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing

On April 1, 2025, Moleculin Biotech announced the commencement of dosing for the first patient in its Phase 3 MIRACLE trial, which evaluates Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia (R/R AML). This trial marks a significant milestone for the company and the AML community, with initial data expected in the second half of 2025. The trial’s adaptive design and global scope aim to accelerate Annamycin’s development towards approval, potentially impacting Moleculin’s market positioning and providing valuable insights for stakeholders.

Moleculin Biotech Shares Corporate Presentation Update

On March 24, 2025, Moleculin Biotech, Inc. utilized a corporate presentation for its website, which was detailed in a Current Report on Form 8-K. The presentation, noted as Exhibit 99.1, was shared for informational purposes and not intended for filing under the Securities Exchange Act of 1934 or the Securities Act of 1933.

Moleculin Biotech Gets FDA Nod for Phase 3 Trial

On February 13, 2025, Moleculin Biotech announced receiving FDA feedback that allows a reduced size for its Phase 3 trial protocol evaluating Annamycin combined with Cytarabine for treating relapsed or refractory AML. This trial, named MIRACLE, will be conducted globally, including in the US, Europe, and the Middle East, and aims to accelerate the approval timeline for this potentially groundbreaking non-cardiotoxic anthracycline. The feedback enables quicker site openings and recruitment, with implications for significantly impacting AML treatment and eliminating cardiotoxic risks in cancer therapies.

Moleculin Biotech Gains European Approval for Phase 3 Trial

On February 11, 2025, Moleculin Biotech announced receiving regulatory approval in Europe to start recruiting for its Phase 3 MIRACLE trial, evaluating Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia. The trial will include sites in the US, Europe, and the Middle East. The announcement signifies a crucial step in advancing their pivotal clinical trial, aiming for unblinded preliminary data from the first 45 subjects in the second half of 2025, potentially enhancing their market position in cancer therapeutics.